Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine for prevention of depression in head and neck cancer
NCT04977271Phase 4Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of venlafaxine in major depressive disorder (MDD), anxiety disorder, pain, sponsored by University of Alabama at Birmingham. Planned start Jan 2024; status: withdrawn.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)anxiety disorderpain
Beyond the preview
Go deeper on NCT04977271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977271.